Arun J. Sanyal
@ArunJSanyalVCU
Followers
843
Following
396
Media
56
Statuses
376
The views expressed here do not necessarily reflect those of VCU or its medical school or the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health.
RVA liver lover since 1989.
Joined August 2023
Glad we now have a second option for our MASH patients.
🚨 Big milestone in MASLD/MASH!.We now have two FDA-approved drugs:.🔸 Resmetirom (oral, THR-β agonist).🔹 Semaglutide (weekly SC, GLP-1 RA). I made this simple side-by-side comparison 👇
0
9
31
W/ @juanpabloarab, "Public health policies to prevent alcohol-related liver disease".
@NatRevGastroHep Just ahead of my birthday, pleased to see two pieces in @NatRevGastroHep this month:.On #public health policies to prevent alcohol-relater liver disease:.And on expanding the MASLD community of practice:.#LiverTwitter #SLDthinktank
1
3
10
RT @AGA_GIHN: We spoke to author @JasmohanBajaj about this study on machine learning ➡️ learn more:
0
1
0
RT @AmJGastro: Enhancement of Cirrhosis Mortality Prediction by Including Hepatic Encephalopathy to MELD 3.0 in a National Veteran Cohort.S….
journals.lww.com
and MELD-sodium (MELD-Na) scores in 75,327 veterans (26.8% with HE, 22% 90-day and 37% 1-year mortality). The addition of HE to MELD 3.0 and MELD-Na significantly improved their mortality prediction...
0
21
0
Thank you, @drmohanv, for this very special award. This was quite an honor. #livertwitter.
Highlights from Day 1 – DMDSC Lifetime Contribution Award. We were honoured to present the prestigious DMDSC Lifetime Contribution Award to Prof. Arun J. Sanyal, Virginia Commonwealth University, USA – in recognition of his extraordinary lifetime achievements in the field of
0
6
23
RT @drmohanv: Highlights from Day 1 – DMDSC Lifetime Contribution Award. We were honoured to present the prestigious DMDSC Lifetime Contrib….
0
3
0
RT @VCU_Liver: 😲 😲 @ArunJSanyalVCU helped to inaugurate the new Liver and Kidney Transplant Operation Theater Complex and an advanced ICU b….
0
2
0
RT @HealioGastro: 🤖🧠 An AI model accurately predicted inpatient death on day 1 of admission in patients with #cirrhosis. Developed by @Jas….
healio.com
A machine learning model may help predict mortality for hospitalized patients with cirrhosis at the time of admission, according to research published in Gastroenterology.The model, which used Random...
0
8
0
RT @VCU_Liver: If you're looking for a world-renowned GI fellowship program, listen/watch @ArunJSanyalVCU discuss the VCU program: No. 9 wo….
0
6
0
RT @JasmohanBajaj: Definitions of #liver failure vary➡️tower of Babel in #ACLF.Enter @CLEARED_liver with 🌎 input (>120 sites) @AGA_CGH .🔑 l….
0
30
0
Thank you, @RadcliffeCVRM, for sharing.
💡Dr @ArunJSanyalVCU shares insights from the phase 3 ESSENCE trial examining #semaglutide 2.4 mg for metabolic dysfunction-associated #steatohepatitis. 📽️Watch here👉 #MASH #CKM #CVRM #CardioX #CardioEd
1
1
11
I am very grateful for our team, who work so hard to make our patients' lives better.
.@ArunJSanyalVCU: This recognition of our high-quality GI-Hep program as one with tremendous academic research performance reflects the wide-ranging expertise of our dedicated faculty and staff, who make the science in our program possible. #livertwitter
1
0
30
Very proud of our fellows!.
Gastroenterology and Transplant Hepatology Fellowship Graduation 👩🎓
0
2
14
ICYMI: I was honored to participate in @EASLedu's recent online presentation, Steatotic Liver Disease Unpacked: Targeting Dynamic Risks. Watch here. #livertwitter .@AleksanderKrag @MeenaBBansal . #EASLStudio #LiverXhttps://bit.ly/3FWSvI3
2
2
21
Honored to host @marurinella.
A real honor and pleasure to host Dr @marurinella at @VCU_Liver who is delivering a brilliant and inspiring lecture in Steatotic Liver Disease… a very exciting field with opportunities to improve clinical care and research @ArunJSanyalVCU @RichSterlingMD
0
2
14
RT @VCU_Liver: 📣Today is Global #fattyliverday! We join @globalliver to raise awareness about #fattyliverdisease in [insert country]. Join….
0
1
0
RT @EASLedu: 🔴 We are now live with @AleksanderKrag, @MeenaBBansal, Mattias Ekstedt and @ArunJSanyalVCU to discuss state-of-the-art diagnos….
0
2
0
RT @EASLedu: Resmetirom was approved for MASH 14 months ago in the US and is likely to gain approval in the EU shortly, with semaglutide cl….
0
4
0
Looking forward to meeting new colleagues in India and discussing the latest in MASLD research.
INASL-2025 .7th - 10th August, 2025.Chandigarh .Single Theme Symposium on MASLD - 7th August (Thursday)
0
0
10
Looking forward to this!.
This week's EASL Studio episode will explore state-of-the-art practices in diagnosing steatotic liver disease and stratifying patients effectively for targeted treatment in 2025. 🗓️ Wednesday 11 June, 18:00 CEST.🔗 @AleksanderKrag @ArunJSanyalVCU
0
2
17